CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia

[1]  Markus G. Manz,et al.  Molecular Minimal Residual Disease in Acute Myeloid Leukemia , 2018, The New England journal of medicine.

[2]  G. Schuurhuis,et al.  Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia , 2018, Journal of visualized experiments : JoVE.

[3]  C. Bloomfield,et al.  Prognostic impact of the CD34+/CD38− cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation , 2017, American journal of hematology.

[4]  E. Vellenga,et al.  Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. , 2017, Blood.

[5]  Claude Preudhomme,et al.  A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.

[6]  P. Vyas,et al.  Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage , 2016, The Journal of experimental medicine.

[7]  Yashma Patel,et al.  Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.

[8]  G. Schuurhuis,et al.  A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia , 2016, Leukemia.

[9]  C. Hourigan,et al.  Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia. , 2015, Seminars in hematology.

[10]  P. Vyas,et al.  An immunophenotypic pre‐treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38low blasts , 2015, British journal of haematology.

[11]  G. Schuurhuis,et al.  Absence of leukaemic CD34+ cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered , 2015, British journal of haematology.

[12]  E. Estey,et al.  Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Vyas,et al.  Prognostic value of monitoring a candidate immunophenotypic leukemic stem/progenitor cell population in patients allografted for acute myeloid leukemia , 2014, Leukemia.

[14]  T. Pabst,et al.  Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia , 2014, PloS one.

[15]  G. Schuurhuis,et al.  Tumor heterogeneity makes AML a “moving target” for detection of residual disease , 2013, Cytometry. Part B, Clinical cytometry.

[16]  Robert K Hills,et al.  Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Bob Löwenberg,et al.  High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Estey,et al.  Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. , 2013, Blood.

[19]  Yu Wang,et al.  MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. , 2013, Blood.

[20]  F. Lo‐Coco,et al.  Identification of emerging FLT3 ITD‐positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin , 2013, British journal of haematology.

[21]  J. Gratama,et al.  Tumor heterogeneity makes AML a "moving target" for detection of residual disease. , 2013, Cytometry. Part B, Clinical cytometry.

[22]  Todd A Alonzo,et al.  Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. , 2012, Blood.

[23]  S. Jang,et al.  Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia , 2012, Annals of Hematology.

[24]  Ø. Bruserud,et al.  The surface molecule signature of primary human acute myeloid leukemia (AML) cells is highly associated with NPM1 mutation status , 2012, Leukemia.

[25]  Y. Assaraf,et al.  The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse , 2012, Leukemia.

[26]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[27]  C. Jordan,et al.  Leukemia stem cells in 2010: current understanding and future directions. , 2011, Blood reviews.

[28]  M. Ebinger,et al.  High Proportion of Leukemic Stem Cells at Diagnosis Is Correlated with Unfavorable Prognosis in Childhood Acute Myeloid Leukemia , 2011, Pediatric hematology and oncology.

[29]  P. Vyas,et al.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.

[30]  M. Carroll,et al.  Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. , 2011, The Journal of clinical investigation.

[31]  D. Gold,et al.  Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse. , 2010, Cancer genetics and cytogenetics.

[32]  Y. Assaraf,et al.  High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. , 2010, Blood.

[33]  J. Gribben,et al.  Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. , 2010, Blood.

[34]  G. Schuurhuis,et al.  Minimal residual disease in acute myeloid leukemia: already predicting a safe haven? , 2010, Expert review of hematology.

[35]  Satoshi Tanaka,et al.  Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region , 2007, Nature Biotechnology.

[36]  Q. Waisfisz,et al.  High Stem Cell Frequency in Acute Myeloid Leukemia at Diagnosis Predicts High Minimal Residual Disease and Poor Survival , 2005, Clinical Cancer Research.

[37]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[38]  G. Schuurhuis,et al.  MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia , 2004, Leukemia.

[39]  D. Olive,et al.  Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. , 2000, Cancer research.

[40]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[41]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[42]  E. Kelemen.  Specific thrombopoietin cloned and sequenced--with personal retrospect and clinical prospects. , 1995, Leukemia.